wire - news in brief
« BACK
Health - Pharmacology - 27.03.2023 
Mathematical Modelling to Inform Next-Generation Malaria Interventions
Global progress against malaria has stagnated and novel medical interventions are urgently needed.
Health - Pharmacology - 21.03.2023
Health - Pharmacology - 16.03.2023 
Immune-cell booster for cancer patients
Cancer patients might one day benefit from being administered immune cells from healthy donors. But as things stand, receiving donor cells can cause severe or even fatal immune reactions. A researcher at ETH Zurich has now developed a technology that avoids these. Edo Kapetanovic is a medical doctor, but for a while now he has devoted himself entirely to research in synthetic immunology.
Health - Pharmacology - 03.03.2023
Health - Pharmacology - 22.02.2023 
When researchers join forces in the fight against cancer
Since 2016, the Swiss Cancer Center Léman provides a space for scientists and clinicians from across the Lake Geneva region to pool their efforts, share insights and work together on innovative cancer treatments.
Pharmacology - Health - 30.01.2023
Health - Pharmacology - 27.01.2023
Health - Pharmacology - 14.12.2022
Pharmacology - Health - 30.11.2022
Health - Pharmacology - 28.11.2022 
Localising BRCA gene mutations to better treat ovarian cancer
An international team highlights the importance of localising BRCA gene mutations for the treatment of ovarian cancer. Mutations of BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 people respectively, significantly increase the risk of certain cancers such as ovarian, breast, pancreatic and prostate cancer.
Health - Pharmacology - 09.11.2022 
Temporary mild damage to heart muscle cells after Covid-19 booster vaccination
An interdisciplinary research team from the University of Basel and the University Hospital Basel has studied the effects of the Covid-19 booster vaccination on the heart muscle.
Health - Pharmacology - 27.10.2022 
Overcoming resistance to colon cancer treatment
A team from the UNIGE has found an alternative for patients who have developed resistance to chemotherapy treatments. Colorectal cancer is one of the most common cancers. Its treatment is mainly based on chemotherapy. However, over time, chemotherapy induces resistance in the majority of patients, who end up being unresponsive to the drugs.
Pharmacology - Life Sciences - 21.09.2022
Health - Pharmacology - 10.06.2022
Health - Pharmacology - 08.06.2022 
Major US award for Bern and Geneva researchers
A prestigious grant from the USA goes to the biomedical scientist Sven Rottenberg, University of Bern, and the clinical scientist Intidhar Labidi-Galy, University of Geneva and University Hospital of Geneva.
Pharmacology - Health - 24.05.2022 
Turning drug discovery into speed dating
EPFL spin-off ArcoScreen has developed a platform that turns the discovery of new drugs for Alzheimer's and Parkinson's disease, diabetes and cancer from a marathon into a sprint. The firm's microfluidic readout system assesses the response of G-protein-coupled receptors (GPCRs) to new substances, delivering significant time and financial gains for pharmaceutical companies.
Health - Pharmacology - 29.04.2022
Health - Pharmacology - 21.03.2022
Pharmacology - Life Sciences - 16.03.2022
Pharmacology - 07.03.2022
Health - Pharmacology - 07.03.2022 
Overcoming resistance to breast cancer treatment
A team from the UNIGE has identified a potential target for restoring the efficacy of standard treatment in resistant patients. Many breast cancer patients develop resistance to standard drug treatments aimed at preventing the growth of cancer cells. A team from the University of Geneva has identified a molecular regulator involved in these resistance mechanisms.
Health - Pharmacology - 28.02.2022 
Therapy for muscular dystrophy: A new start-up at the Biozentrum
Prof. Markus Rüegg and Dr. Judith Reinhard from the Biozentrum of the University of Basel have founded the start-up SEAL Therapeutics AG together with Dr. Thomas Meier, former CEO of Santhera Pharmaceuticals.
Health - Pharmacology - 21.02.2022
Pharmacology - Health - 16.02.2022
Health - Pharmacology - 14.02.2022
Health - Pharmacology - 10.02.2022 
ANTICOV: Clinical Trial for COVID-19 in Low-resource Settings to Test a New Drug Combination
The need for effective COVID-19 treatments remains particularly acute, especially in sub-Saharan Africa where access to vaccines is still extremely limited.
Health - Pharmacology - 02.02.2022
Health - Pharmacology - 26.01.2022
Health - Pharmacology - 24.12.2021
Health - Pharmacology - 13.12.2021
Pharmacology - Health - 11.12.2021
Health - Pharmacology - 06.12.2021
Pharmacology - Life Sciences - 02.12.2021 
Innovative research into new vaccines
Projects taking part in the National Research Programme "Covid-19" (NRP 78) of the Swiss National Science Foundation (SNSF) are pursuing highly promising approaches in a drive to develop new vaccines.
Pharmacology - Health - 29.11.2021
Event - Pharmacology - 23.11.2021
Environment - Pharmacology - 17.11.2021 
World Toilet Day 2021: The toilet revolution is here
In professional circles, there is talk of a toilet revolution. What exactly is going on here? It is not only about the toilet itself, but also highly about the treatment of excreta.
Pharmacology - Health - 16.11.2021
Pharmacology - 15.11.2021
Health - Pharmacology - 12.11.2021
Health - Pharmacology - 11.11.2021
Pharmacology - Health - 09.11.2021 
A first for Switzerland: proton therapy to treat lung cancer
Today a 60-year-old patient suffering from lung cancer received proton beam therapy, a medical procedure where positively charged particles are precisely targeted at the tumour. This is the first time this type of radiotherapy has been used for lung cancer treatment in Switzerland. The 7-week course of treatment is part of an international clinical trial in which the PSI and cantonal hospitals in Aarau are taking part.
Health - Pharmacology - 25.10.2021
Pharmacology - Health - 22.10.2021
Pharmacology - 20.10.2021
Health - Pharmacology - 15.10.2021
Pharmacology - Health - 15.10.2021
Pharmacology - Health - 14.10.2021
Health - Pharmacology - 14.10.2021
Health - Pharmacology - 08.10.2021 
Wyss Center announces new collaboration to improve brain tumor treatment
Translational project will create the first detailed 3D maps of human glioblastomas with an integrated 'tissue time machine' to predict response to therapies Geneva, Switzerland - The Wyss Center ann
Health - Pharmacology - 08.10.2021
Pharmacology
Results 1 - 50 of 1699.
Global progress against malaria has stagnated and novel medical interventions are urgently needed.
Cancer patients might one day benefit from being administered immune cells from healthy donors. But as things stand, receiving donor cells can cause severe or even fatal immune reactions. A researcher at ETH Zurich has now developed a technology that avoids these. Edo Kapetanovic is a medical doctor, but for a while now he has devoted himself entirely to research in synthetic immunology.
A potential new treatment for prostate cancer
Researchers at the Institute of oncology research (IOR, affiliated to USI and member of Bios+ ) , in collaboration with researchers from the University of Padova, have made a groundbreaking discovery that could change the way we think about ageing and immune cells offering a potential new target for treatments in cases of prostate cancer.
Researchers at the Institute of oncology research (IOR, affiliated to USI and member of Bios+ ) , in collaboration with researchers from the University of Padova, have made a groundbreaking discovery that could change the way we think about ageing and immune cells offering a potential new target for treatments in cases of prostate cancer.
Since 2016, the Swiss Cancer Center Léman provides a space for scientists and clinicians from across the Lake Geneva region to pool their efforts, share insights and work together on innovative cancer treatments.
Antibodies against coronaviruses coldspots discovered
The coronavirus keeps evolving, and in doing so, it evades our immune defences. But does the entire coronavirus evolve, or do some portions remain unchanged? Sieving through over 10 million coronavirus sequences, two PhD students at the Institute for Research in Biomedicine (IRB, Switzerland, affiliated with the Università della Svizzera italiana) discovered that some portions of the virus spike (the molecule on the virus that is key to infect human cells) were remarkably conserved.
The coronavirus keeps evolving, and in doing so, it evades our immune defences. But does the entire coronavirus evolve, or do some portions remain unchanged? Sieving through over 10 million coronavirus sequences, two PhD students at the Institute for Research in Biomedicine (IRB, Switzerland, affiliated with the Università della Svizzera italiana) discovered that some portions of the virus spike (the molecule on the virus that is key to infect human cells) were remarkably conserved.
More Precise Treatment
The LOOP Zurich research center combines expertise from ETH Zurich, the University of Zurich and the four university hospitals in Zurich with the aim of developing more personalized therapies.
The LOOP Zurich research center combines expertise from ETH Zurich, the University of Zurich and the four university hospitals in Zurich with the aim of developing more personalized therapies.
An international team highlights the importance of localising BRCA gene mutations for the treatment of ovarian cancer. Mutations of BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 people respectively, significantly increase the risk of certain cancers such as ovarian, breast, pancreatic and prostate cancer.
An interdisciplinary research team from the University of Basel and the University Hospital Basel has studied the effects of the Covid-19 booster vaccination on the heart muscle.
A team from the UNIGE has found an alternative for patients who have developed resistance to chemotherapy treatments. Colorectal cancer is one of the most common cancers. Its treatment is mainly based on chemotherapy. However, over time, chemotherapy induces resistance in the majority of patients, who end up being unresponsive to the drugs.
A prestigious grant from the USA goes to the biomedical scientist Sven Rottenberg, University of Bern, and the clinical scientist Intidhar Labidi-Galy, University of Geneva and University Hospital of Geneva.
EPFL spin-off ArcoScreen has developed a platform that turns the discovery of new drugs for Alzheimer's and Parkinson's disease, diabetes and cancer from a marathon into a sprint. The firm's microfluidic readout system assesses the response of G-protein-coupled receptors (GPCRs) to new substances, delivering significant time and financial gains for pharmaceutical companies.
Three Simple Interventions for Cancer Prevention in Older People
A combination of high-dose vitamin D, omega-3 fatty acids and a simple home strength exercise program (SHEP) can cumulatively reduce the risk of cancer in healthy adults over the age of 70 by 61 percent, the international DO-HEALTH study led by the University of Zurich has shown. It is the first study to test the combined benefit of three affordable public health interventions for the prevention of invasive cancers.
A combination of high-dose vitamin D, omega-3 fatty acids and a simple home strength exercise program (SHEP) can cumulatively reduce the risk of cancer in healthy adults over the age of 70 by 61 percent, the international DO-HEALTH study led by the University of Zurich has shown. It is the first study to test the combined benefit of three affordable public health interventions for the prevention of invasive cancers.
A novel painless and reliable allergy test
Although allergies are widespread, their diagnosis is complex and, depending on the type of allergy, the prospects of success with therapy are not always clear.
Although allergies are widespread, their diagnosis is complex and, depending on the type of allergy, the prospects of success with therapy are not always clear.
Swiss vaccine candidates enter clinical trial phase
Researchers from Bern, Geneva, Berlin and Riems are developing two vaccine candidates against SARS-CoV-2.
Researchers from Bern, Geneva, Berlin and Riems are developing two vaccine candidates against SARS-CoV-2.
A team from the UNIGE has identified a potential target for restoring the efficacy of standard treatment in resistant patients. Many breast cancer patients develop resistance to standard drug treatments aimed at preventing the growth of cancer cells. A team from the University of Geneva has identified a molecular regulator involved in these resistance mechanisms.
Prof. Markus Rüegg and Dr. Judith Reinhard from the Biozentrum of the University of Basel have founded the start-up SEAL Therapeutics AG together with Dr. Thomas Meier, former CEO of Santhera Pharmaceuticals.
The need for effective COVID-19 treatments remains particularly acute, especially in sub-Saharan Africa where access to vaccines is still extremely limited.
Projects taking part in the National Research Programme "Covid-19" (NRP 78) of the Swiss National Science Foundation (SNSF) are pursuing highly promising approaches in a drive to develop new vaccines.
In professional circles, there is talk of a toilet revolution. What exactly is going on here? It is not only about the toilet itself, but also highly about the treatment of excreta.
Today a 60-year-old patient suffering from lung cancer received proton beam therapy, a medical procedure where positively charged particles are precisely targeted at the tumour. This is the first time this type of radiotherapy has been used for lung cancer treatment in Switzerland. The 7-week course of treatment is part of an international clinical trial in which the PSI and cantonal hospitals in Aarau are taking part.
Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research
The AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine's pioneering leadership in genomic science.
The AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine's pioneering leadership in genomic science.
TB-PRACTECAL: Clinical Trial Yields Promising Results for Drug-Resistant Tuberculosis Treatment
TB-PRACTECAL, a clinical trial led by Médecins Sans Frontières with partners including Swiss TPH, has found that a new all-oral treatment regimen for rifampicin-resistant tuberculosis (RR-TB) is safer and more effective than the current accepted standard of care.
TB-PRACTECAL, a clinical trial led by Médecins Sans Frontières with partners including Swiss TPH, has found that a new all-oral treatment regimen for rifampicin-resistant tuberculosis (RR-TB) is safer and more effective than the current accepted standard of care.
Roche’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma
Short duration infusion of Gazyvaro (obinutuzumab) is administered with a target infusion time of 90 minutes, compared to the current standard infusion time of approximately three to four hours Resul
Short duration infusion of Gazyvaro (obinutuzumab) is administered with a target infusion time of 90 minutes, compared to the current standard infusion time of approximately three to four hours Resul
Translational project will create the first detailed 3D maps of human glioblastomas with an integrated 'tissue time machine' to predict response to therapies Geneva, Switzerland - The Wyss Center ann
